NASDAQ:YARW

Yarrow Bioscience Q1 2025 Earnings Results & Report

Yarrow Bioscience logo
$14.35 +0.00 (+0.03%)
As of 11:12 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Yarrow Bioscience beat analyst expectations on both earnings and revenue in its Q1 2025 results, released May 8, 2025. The company reported EPS of -$10.00 versus the -$14.50 consensus estimate, while revenue of $200 thousand topped the $50 thousand estimate by $150.00 thousand.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Yarrow Bioscience EPS Results

Actual EPS
-$10.00
Consensus EPS
-$14.50
Beat/Miss
Beat by +$4.50
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Yarrow Bioscience Revenue Results

Actual Revenue
$200 thousand
Expected Revenue
$50 thousand
Beat/Miss
Beat by +$150.00 thousand
YoY Revenue Growth
N/A

Yarrow Bioscience Q1 2025 Earnings FAQ

Yarrow Bioscience (NASDAQ:YARW) reported earnings of -$10.00 per share for Q1 2025, beating the consensus estimate of -$14.50. The report was announced on Thursday, May 8, 2025.

Yarrow Bioscience reported revenue of $200 thousand for Q1 2025, against a consensus estimate of $50 thousand.

Yarrow Bioscience Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Yarrow Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Yarrow Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Yarrow Bioscience and other key companies, straight to your email.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

View Yarrow Bioscience Profile